Drug Trial Radar · NCT07102316
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Aug 19, 2025
Primary completion
Oct 25, 2025
Study completion Nov 3, 2025
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the relative bioavailability of treprostinil (TRE) between the TPIP F2 and TPIP F3 at 3 capsule strengths, dose A, dose B, and dose C, in healthy participants following a single inhalation of TPIP dose.
Conditions
- Healthy Volunteers
Interventions
TPIP F2Drug
Inhalation using a capsule-based dry powder inhaler device.
TPIP F3Drug
Inhalation using a capsule-based dry powder inhaler device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of Treprostinil (TRE)Time frame: Pre-dose and post-dose at multiple timepoints up to Day 10
- Area Under Plasma Concentration-Time Curve From 0 to Last Time Point With Quantifiable Concentration (AUClast) of TRETime frame: Pre-dose and post-dose at multiple timepoints up to Day 10
- Area Under Plasma Concentration-Time Curve From 0 to Infinity (AUCinf) of TRETime frame: Pre-dose and post-dose at multiple timepoints up to Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USA001
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.